课题基金 / 基金详情

Hypertension and Collagen: Effect of Ac-SDKP

Hypertension and Collagen: Effect of Ac-SDKP
高血压和胶原蛋白:Ac-SDKP 的作用
批准号:
6831679
负责人:
NOUR-EDDINE RHALEB
金额:
$28.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-01 至 2006-12-31

项目摘要

项目成果

NOUR-EDDINE RHALEB的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
EXCEED THE SPACE PROVIDED. Hypertension causes left ventricular hypertrophy (LVH) and increased LV interstitialand perivascular collagen deposition. Increased cardiac collagen may alter function in hypertrophied hearts. Angiotensin- converting enzyme inhibition(ACEi) haves been shown to reverse LVH in hypertension. This effect has been attributed to blockade of angiotensin II (Ang II) formation and kinin degradation. We have shownthat N-acetyl-seryl-aspartyl-lysyl-proline(Ac-SDKP), another natural substrate for ACE, prevents LV monocyte/macrophage infiltrationand fibrosiswithout altering blood pressure (BP) or LVH in hypertension. We believe this is the first demonstration that Ac-SDKP affects cardiac fibrosis; however, the mechanism(s) or receptor(s) by which Ac-SDKP affords cardioprotectionare not known, nor whether Ac-SDKP contributes to the cardioprotectiveeffects of ACEi. We hypothesizethat (1) Ac-SDKP has an anti-inflammatoryand antifibroticeffect on the heart in hypertension via specific receptor(s) linkedto a cascade of signal transduction, including MAP kinase, protein kinase C (PKC), NF-kB and TGF-beta, and (2) the effect of ACEi on the heart is mediated in part by Ac-SDKP. In aim new analogues of Ac-SDKP and SDK fragments will be synthesized and tested to identify (1) an ACE-resistant analogue with an inhibitory effect similar to Ac-SDKP that can be radiolabeled and used to characterize Ac-SDKP receptor(s), and (2) an antagonist that specifically blocksthe inhibitory effect of Ac-SDKP. In aim II we will determine whether (1) the effect of Ac- SDKP is linked to suppression of TGF-beta, CTGF and Smad expression, and (2) the effect of TGF-beta on collagen type I and/or III expression is affected by Ac-SDKP. We will also examine whether Ac-SDKP inhibitsp38 and PKC activationin fibroblasts. In aim IV we will determine whether in vivo Ac-SDKP (1) inhibitsinflammatory cell infiltrationin the LV, p42/p44, p38 and/or PKC activity, NF-kB ,TGF-beta, CTGF and Smads, (2) regresses cardiac fibroblast proliferation,collagen expression and synthesis, (3) increases matrix metalloproteinase activity, and (4) decreases cardiac expression of collagen I and III in rats with long- term hypertension. In aim IV we will examine whether the effect of ACE inhibitionon LV collagen deposition is mediated by Ac-SDKP. This project will provide important new information on the on the cardioprotective effect of ACEi in hypertension and the mechanism of action of Ac-SDKP. PERFORMANCESITE( ========================================Section End===========================================
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ac-SDKP in the Treatment of Cardiac Dysfunction in Hypertension or Ischemic
  • 批准号:
    10336561
  • 项目类别:
  • 资助金额:
    $47.45万
  • 财政年份:
    2021
  • 负责人:
    NOUR-EDDINE RHALEB
  • 依托单位:
Hypertension and Collagen: Effect of Ac-SDKP
  • 批准号:
    7319008
  • 项目类别:
  • 资助金额:
    $36.25万
  • 财政年份:
    2003
  • 负责人:
    NOUR-EDDINE RHALEB
  • 依托单位:
Hypertension and Collagen: Effect of Ac-SDKP
  • 批准号:
    7656903
  • 项目类别:
  • 资助金额:
    $36.25万
  • 财政年份:
    2003
  • 负责人:
    NOUR-EDDINE RHALEB
  • 依托单位:
Hypertension and Collagen: Effect of Ac-SDKP
  • 批准号:
    6558190
  • 项目类别:
  • 资助金额:
    $28.6万
  • 财政年份:
    2003
  • 负责人:
    NOUR-EDDINE RHALEB
  • 依托单位:
海外基金